Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Rating of “Hold” by Brokerages

Vyome Holdings, Inc. (NASDAQ:HIND) has been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.00.

Several research firms have recently weighed in on HIND. Zacks Research upgraded Vyome to a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Finally, Litchfield Hills Research began coverage on Vyome in a research report on Monday, May 4th. They issued a “buy” rating on the stock.

Institutional Investors Weigh In On Vyome

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome as of its most recent SEC filing. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Stock Up 0.9%

NASDAQ HIND opened at $2.18 on Friday. The stock has a market cap of $15.30 million, a P/E ratio of -0.18 and a beta of 1.48. The company’s 50-day simple moving average is $2.17 and its 200 day simple moving average is $2.31. Vyome has a twelve month low of $1.75 and a twelve month high of $16.00.

Vyome (NASDAQ:HIND) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%. Research analysts anticipate that Vyome will post -0.6 earnings per share for the current year.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.